Permanent Fillers

  • Márcio Soares SerraEmail author
  • Leonardo Zacharias Gonçalves
Living reference work entry

Latest version View entry history

Part of the Clinical Approaches and Procedures in Cosmetic Dermatology book series (CAPCD)


Permanent fillers are mainly used in the correction of furrows and deep lines of the skin that are beyond the normal facial wrinkles that appear with aging. They can be an excellent option in facial rejuvenation, especially when there is need for facial and body volume restoration, such as in HIV lipodystrophy. Of the permanent fillers currently available, polymethyl methacrylate (PMMA) is the most commonly used, and has been shown to be safe, effective, and long lasting.


Silicone Polyacrylamide Polyalkylimide Polymethyl methacrylate PMMA Fillers Lipoatrophy HIV Lipodystrophy 


  1. Carvalho Costa IM, Salaro CP, Costa MC. Polymethylmethacrylate facial implant: a successful personal experience in Brazil for more than 9 years. Dermatol Surg. 2009;35:1221–7.CrossRefGoogle Scholar
  2. Casavantes LC. Biopolymerer polyalkilimide (Bio-Alcamid™), high-volume filling material for facial recontuction in patients with HIV-related facial lipoatrophy. Presentation of 100 cases. Dermatolgía CMQ. 2004;2(4):226–33.Google Scholar
  3. Fisher J, Metzler G, Shaler M. Cosmetic permanent fillers for soft tissue augmentation. Arch Dermatol. 2007;143:507–10.Google Scholar
  4. Jones DH, Carruthers A, Fitzgerald R, Sarantopoulos GP. Late-appearing abcesses after injection of non-absorbable hydrogel polymer for HIV-associated facial lipoatrophy. Dermatol Surg. 2007;33:s.193–8.Google Scholar
  5. Jones DH, Carruthers A, Orentreich D, et al. Highly purified 1000-cST silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: an open pilot trial. Dermatol Surg. 2004;30:1279–86.PubMedGoogle Scholar
  6. Lemperle G, Gauthien-Hazn N, Wolters M, Eisemann-Klein M, Zimmermann U, Duffy DM. Foreign body granuloma after all injectable dermal fillers: part 1. Plast Reconstr Surg. 2009;123:1.CrossRefGoogle Scholar
  7. Lemperle G, Hazan-Gautier N, Lemperle M. PMMA microspheres (Artecoll) for long-lasting correction of wrinkles: refinements and statistical results. Aesthet Plast Surg. 1998;22:356–65.CrossRefGoogle Scholar
  8. Lemperle G, Romano JJ, Busso M. Soft tissue augmentation with Aretecoll: 10-year history, indications, technique, and potential side effects. 27th Annual Meeting of Canadian Society of Aesthetic Cosmetic Plastic Surgery; Sep 8–9; Montreal; 2000.Google Scholar
  9. Orsi AT, Miranda AE, Souza AC, Silva LC, Dias GR, et al. Lipoatrophy in patients with AIDS: treatment with polymethylmethacrylate in Amazonas, Brazil. Int J Dermatol. 2011;50CrossRefGoogle Scholar
  10. Pereira SBG, Poralla F. Correção de lipodistrofias faciais com uso de polimetilmetacrilato coloidal (PMMA) em pacientes HIV positivos sob terapia anti-retroviral. 8° Congresso Brasileiro de Medicina Estética. Salvador: Comunicação livre; 2001.Google Scholar
  11. Rorich RJ, Nguyen AT, Kenkel JM. Lexicon for soft tissue implants. Dermatol Surg. 2009;35:1605–11.CrossRefGoogle Scholar
  12. Serra M. Correction of facial lipodystrophy with polymethylmethacrylate with polymethylmethacrylate on HIV patients [abstract no. HL1130]. 2nd World Congress of the International Academy of Cosmetic Dermatology. Rio de Janeiro; 2000 Nov.Google Scholar
  13. Serra M. Facial implants with polymethylmethacrylate for lipodystrophy correction: 30 months follow-up. 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Athens, Oct 2001 [abstract no. P114]. Antivir Ther 2001 Oct; 6(suppl 4):75.Google Scholar
  14. Serra M. Soft tissue augmentation with polymethymethacrylate (PMMA) for correction of facial atrophy [abstract no. O-7]. 3rd European Workshop on Lipodystrophy and Metabolic Disorders. Marbella; 2002a Apr.Google Scholar
  15. Serra M. Facial implants with polymethylmethacrylate (PMMA) for lipodystrophy correction: 36 months follow up [abstract no. ThPeB 7378]. XIV International AIDS Conference. Barcelona; 2002b Jul.Google Scholar
  16. Serra MS, Oyafuso LK, Trope BM. Polymethylmethacrylate (PMMA) for facial atrophy treatment: 5 years follow-up [abstract no. MoOrB1060]. XV International AIDS Conference, Bangkok, July 11–16 2004.Google Scholar
  17. Serra M, Gonçalves LZ, Gontijo SG. Treatment of HIV-related facial and body lipodystrophy with polymethylmethacrylate (PMMA); 10 years experience [abstract no. P-72]. 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. London, UK, Nov 2008. Antivir Ther 2008; 13(suppl 4):A75.Google Scholar
  18. Serra MS, Oyafuso LK, Trope BM, Munhoz Leite OH, Ramos-E-Silva M. An index for staging and evaluation of the efficacy of the treatment with polymethylmethacrylate in HIV/AIDS patients: a pilot study. J Eur Acad Dermatol Venereol. 2013;27(8):990–6.CrossRefGoogle Scholar
  19. Serra MS, Gonçalves LZ, Ramos-e-silva M. Soft tissue augmentation with PMMA-microspheres for the treatment of HIV-associated buttock lipodystrophy. Int J STD AIDS, Mar 2015. 26: 279–284.Google Scholar
  20. Soares FMG, Costa IMC. Lipoatrofia associada ao HIV/Aids: do advent aos conhecimentos atuais. An Bras Dermatol. 2011;86(5):843–64.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Márcio Soares Serra
    • 1
    • 2
    • 3
    • 4
    Email author
  • Leonardo Zacharias Gonçalves
    • 3
  1. 1.DermatologyFederal University of The State of Rio de JaneiroRio de JaneiroBrazil
  2. 2.Cosmiatric Dermatology, Gaffrèe and Guinle University HospitalRio de JaneiroBrazil
  3. 3.Brazilian Society of DermatologyRio de JaneiroBrazil
  4. 4.American Academy DermatologyScaumburgUSA

Personalised recommendations